Format

Send to:

Choose Destination
See comment in PubMed Commons below
Lancet Oncol. 2012 Jun;13(6):e249-58. doi: 10.1016/S1470-2045(12)70073-6.

microRNAs in cancer management.

Author information

  • 1Toxicology Unit, Medical Research Council, Lancaster Road, Leicester, UK.

Abstract

Since the identification of microRNAs (miRNAs) in 1993, and the subsequent discovery of their highly conserved nature in 2000, the amount of research into their function--particularly how they contribute to malignancy--has greatly increased. This class of small RNA molecules control gene expression and provide a previously unknown control mechanism for protein synthesis. As such, it is unsurprising that miRNAs are now known to play an essential part in malignancy, functioning as tumour suppressors and oncogenes. This Review summarises the present understanding of how miRNAs operate at the molecular level; how their dysregulation is a crucial part of tumour formation, maintenance, and metastasis; how they can be used as biomarkers for disease type and grade; and how miRNA-based treatments could be used for diverse types of malignancies.

Copyright © 2012 Elsevier Ltd. All rights reserved.

PMID:
22652233
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk